Literature DB >> 16940271

Use of memantine to treat Alzheimer's disease.

Serge Gauthier, Nathan Herrmann, Florian Ferreri, Catherine Agbokou, Catherine Agokou.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16940271      PMCID： PMC1550762          DOI： 10.1503/cmaj.1060168

Source DB:  PubMed          Journal:  CMAJ        ISSN： 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  8 in total

Review 1.  Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond.

Authors:  Stuart A Lipton
Journal:  Nat Rev Drug Discov       Date:  2006-02       Impact factor: 84.694

2.  Managing discontinuation syndrome in patients with dementia.

Authors:  Serge Gauthier
Journal:  J Psychiatry Neurosci       Date:  2006-01       Impact factor: 6.186

3.  Memantine in moderate-to-severe Alzheimer's disease.

Authors:  Barry Reisberg; Rachelle Doody; Albrecht Stöffler; Frederick Schmitt; Steven Ferris; Hans Jörg Möbius
Journal:  N Engl J Med       Date:  2003-04-03       Impact factor: 91.245

4.  Memantine in severe dementia: results of the 9M-Best Study (Benefit and efficacy in severely demented patients during treatment with memantine).

Authors:  B Winblad; N Poritis
Journal:  Int J Geriatr Psychiatry       Date:  1999-02       Impact factor: 3.485

5.  Rivastigmine monotherapy and combination therapy with memantine in patients with moderately severe Alzheimer's disease who failed to benefit from previous cholinesterase inhibitor treatment.

Authors:  T Dantoine; S Auriacombe; M Sarazin; H Becker; J-J Pere; I Bourdeix
Journal:  Int J Clin Pract       Date:  2006-01       Impact factor: 2.503

6.  Effects of memantine on behavioural symptoms in Alzheimer's disease patients: an analysis of the Neuropsychiatric Inventory (NPI) data of two randomised, controlled studies.

Authors:  S Gauthier; Y Wirth; H J Möbius
Journal:  Int J Geriatr Psychiatry       Date:  2005-05       Impact factor: 3.485

7.  Tolerability of memantine in combination with cholinesterase inhibitors in dementia therapy.

Authors:  Susanne Hartmann; Hans Jörg Möbius
Journal:  Int Clin Psychopharmacol       Date:  2003-03       Impact factor: 1.659

8.  Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial.

Authors:  Pierre N Tariot; Martin R Farlow; George T Grossberg; Stephen M Graham; Scott McDonald; Ivan Gergel
Journal:  JAMA       Date:  2004-01-21       Impact factor: 56.272
  8 in total
  4 in total

Review 1.  Biological Potential, Gastrointestinal Digestion, Absorption, and Bioavailability of Algae-Derived Compounds with Neuroprotective Activity: A Comprehensive Review.

Authors:  Bruna Martins; Mónica Vieira; Cristina Delerue-Matos; Clara Grosso; Cristina Soares
Journal:  Mar Drugs       Date:  2022-05-28       Impact factor: 6.085

2.  N-Methyl-D-Aspartate Antagonists and Steroids for the Prevention of Persisting Post-Surgical Pain After Thoracoscopic Surgeries: A Randomized Controlled, Factorial Design, International, Multicenter Pilot Trial.

Authors:  Harsha Shanthanna; Alparslan Turan; Jessica Vincent; Remie Saab; Yaron Shargall; Turlough O'Hare; Kimberly Davis; Sylvanus Fonguh; Kumar Balasubramaniam; James Paul; Ian Gilron; Henrik Kehlet; Daniel I Sessler; Mohit Bhandari; Lehana Thabane; P J Devereaux
Journal:  J Pain Res       Date:  2020-02-12       Impact factor: 3.133

3.  DMSO Delays Alzheimer Disease Causing Aβ-induced Paralysis in C. elegans Through Modulation of Glutamate/Acetylcholine Neurotransmission.

Authors:  Girish Sadananda; Janaki Devi Velmurugan; Jamuna R Subramaniam
Journal:  Ann Neurosci       Date:  2021-10-05

Review 4.  Stem cell delivery of therapies for brain disorders.

Authors:  Alexander Aleynik; Kevin M Gernavage; Yasmine Sh Mourad; Lauren S Sherman; Katherine Liu; Yuriy A Gubenko; Pranela Rameshwar
Journal:  Clin Transl Med       Date:  2014-07-19
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.